Legend Capital’s Portfolio Company Xbiome Acquires Clinical-Stage Program Targeting Ulcerative Colitis
Legend Capital’s Portfolio Company Xbiome Acquires Clinical-Stage Program Targeting Ulcerative Colitis

HONG KONG, Apr 27, 2022 – (ACN Newswire via SEAPRWire.com) – Legend Capital’s portfolio company Xbiome Inc., an industry-leading and AI-driven microbiome therapeutics company, recently announced that it acquired the clinical-stage M201 program from Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and other viral diseases. Founded in 2017,... » read more

Altamira Therapeutics and Nuance Pharma Enter Into Exclusive Licensing and Distribution Agreement for Bentrio in China and Additional Asian Markets
Altamira Therapeutics and Nuance Pharma Enter Into Exclusive Licensing and Distribution Agreement for Bentrio in China and Additional Asian Markets

Hamilton, Bermuda, Mar 4, 2022 – (ACN Newswire via SEAPRWire.com) – Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, announced today that it has entered into an exclusive licensing and distribution agreement (the “Agreement”) for Bentrio(TM), its nasal spray... » read more

Oculis Strengthens Leading Ophthalmology Pipeline by In-Licensing Neuroprotective Drug Candidate for Glaucoma from Accure Therapeutics
Oculis Strengthens Leading Ophthalmology Pipeline by In-Licensing Neuroprotective Drug Candidate for Glaucoma from Accure Therapeutics

Lausanne, Switzerland, and Barcelona, Spain, Mar 2, 2022 – (ACN Newswire via SEAPRWire.com) – Oculis S.A., (Oculis) a global ophthalmology company developing life-changing treatments to save sight and improve eye care with breakthrough innovations, and Accure Therapeutics, a private translational neuroscience R&D company, today announced a licensing agreement granting Oculis exclusive global rights to develop... » read more

Moderna Announces Plan to Expand Footprint in Asia with Four Additional Subsidiaries
Moderna Announces Plan to Expand Footprint in Asia with Four Additional Subsidiaries

Cambridge, MA, Feb 16, 2022 – (ACN Newswire via SEAPRWire.com) – Moderna, Inc., (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced plans to expand its commercial network across Asia with the addition of four new subsidiaries in Malaysia, Taiwan, Singapore, and Hong Kong. This expansion comes as the Company... » read more

Apollomics, Inc. and Iterion Therapeutics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Tegavivint in Greater China
Apollomics, Inc. and Iterion Therapeutics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Tegavivint in Greater China

FOSTER CITY, Calif. and HANGZHOU, China and HOUSTON, Texas, Feb 11, 2021 – (ACN Newswire) – Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, and Iterion Therapeutics, Inc., a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics, today announced an exclusive collaboration and license... » read more

Fujitsu: Establishment of Joint Venture Aimed at the Development of Therapeutics for the Treatment of Coronavirus Disease
Fujitsu: Establishment of Joint Venture Aimed at the Development of Therapeutics for the Treatment of Coronavirus Disease

TOKYO, Nov 13, 2020 – (JCN Newswire) – PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (TSE:4587), Fujitsu Limited (TSE:6702), Mizuho Capital Co., Ltd. which is a consolidated subsidiary of Mizuho Financial Group, Inc., Takenaka Corporation and KISHIDA CHEMICAL CO., LTD. have agreed today to establish PeptiAID Inc., a joint venture company that will research and... » read more